ESTOCOLMO–(BUSINESS WIRE)–Mentimeter lanza un paquete de herramientas de interacción que incluye tres nuevas herramientas: Menti Live, Menti Form y Menti Pulse. A través de la interacción, los datos y las recomendaciones, este nuevo paquete permite a las organizaciones interactuar con las personas en directo, recabar opiniones de forma asíncrona y realizar un seguimiento de los indicadores importantes a lo largo del tiempo. El lanzamiento de hoy amplía la plataforma de Mentimeter más allá de

NEW YORK–(BUSINESS WIRE)– #creditratingagency–KBRA assigns preliminary ratings to ten classes of mortgage pass-through certificates from CROSS 2026-NQM11 Mortgage Trust, an RMBS transaction issued under the CROSS shelf that is managed by CrossCountry Capital, LLC (“CCC”). CROSS 2026-NQM11 is a co-sponsored transaction with CCC and APF II RESI O4B, LLC. This $735.3 million transaction is collateralized by a pool of 1,481 residential mortgages, including a meaningful concentration of collateral that KBRA considers

Luxembourg – 23 September 2026 – Subsea 7 S.A today announced the award by Turkish Petroleum Offshore Technology Center AS (TP-OTC) of a sizeable1 extension to its Sakarya Phase 3 contract offshore Türkiye, strengthening its contribution to the next phase of the landmark Black Sea gas development.

The additional scope covers towing and mooring line installation and connection activities related to the commissioning of the development’s floating production unit in 2028. Project management and engineering will be led from Subsea7’s office in Istanbul, Türkiye, with work commencing immediately.

This award further reinforces Subsea7’s long-standing presence in the region and its commitment to supporting the safe and efficient delivery of critical offshore energy infrastructure.

  1. Subsea7 defines a sizeable contract as being between $50 million and $150 million

*******************************************************************************
Subsea7 is a global leader in the delivery of offshore projects and services for the evolving energy industry, creating sustainable value by being the industry’s partner and employer of choice in delivering the efficient offshore solutions the world needs.

Subsea7 is listed on the Oslo Børs (SUBC), ISIN LU0075646355, LEI 222100AIF0CBCY80AH62.

*******************************************************************************

Contact for investment community enquiries:
Katherine Tonks
Investor Relations Director
Tel +44 20 8210 5568

ir@subsea7.com

Contact for media enquiries:
Eugenie Sevriugina
Communication Manager
Tel +33 7 88 10 31 25
eugenie.sevriugina@subsea7.com

www.subsea7.com

Forward-Looking Statements: This document may contain ‘forward-looking statements’ (within the meaning of the safe harbour provisions of the U.S. Private Securities Litigation Reform Act of 1995). These statements relate to our current expectations, beliefs, intentions, assumptions or strategies regarding the future and are subject to known and unknown risks that could cause actual results, performance or events to differ materially from those expressed or implied in these statements. Forward-looking statements may be identified by the use of words such as ‘anticipate’, ‘believe’, ‘estimate’, ‘expect’, ‘future’, ‘goal’, ‘intend’, ‘likely’ ‘may’, ‘plan’, ‘project’, ‘seek’, ‘should’, ‘strategy’ ‘will’, and similar expressions. The principal risks which could affect future operations of the Group are described in the ‘Risk Management’ section of the Group’s Annual Report and Consolidated Financial Statements. Factors that may cause actual and future results and trends to differ materially from our forward-looking statements include (but are not limited to): (i) our ability to deliver fixed price projects in accordance with client expectations and within the parameters of our bids, and to avoid cost overruns; (ii) our ability to collect receivables, negotiate variation orders and collect the related revenue; (iii) our ability to recover costs on significant projects; (iv) capital expenditure by oil and gas companies, which is affected by fluctuations in the price of, and demand for, crude oil and natural gas; (v) unanticipated delays or cancellation of projects included in our backlog; (vi) competition and price fluctuations in the markets and businesses in which we operate; (vii) the loss of, or deterioration in our relationship with, any significant clients; (viii) the outcome of legal proceedings or governmental inquiries; (ix) uncertainties inherent in operating internationally, including economic, political and social instability, boycotts or embargoes, labour unrest, changes in foreign governmental regulations, corruption and currency fluctuations; (x) the effects of a pandemic or epidemic or a natural disaster; (xi) liability to third parties for the failure of our joint venture partners to fulfil their obligations; (xii) changes in, or our failure to comply with, applicable laws and regulations (including regulatory measures addressing climate change); (xiii) operating hazards, including spills, environmental damage, personal or property damage and business interruptions caused by adverse weather; (xiv) equipment or mechanical failures, which could increase costs, impair revenue and result in penalties for failure to meet project completion requirements; (xv) the timely delivery of vessels on order and the timely completion of ship conversion programmes; (xvi) our ability to keep pace with technological changes and the impact of potential information technology, cyber security or data security breaches; (xvii) global availability at scale and commercially viability of suitable alternative vessel fuels; and (xviii) the effectiveness of our disclosure controls and procedures and internal control over financial reporting. Many of these factors are beyond our ability to control or predict. Given these uncertainties, you should not place undue reliance on the forward-looking statements. Each forward-looking statement speaks only as of the date of this document. We undertake no obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act. 

This stock exchange release was published by Katherine Tonks, Investor Relations, Subsea7, on 23 September 2026 at 17:15 CET.

Attachment

On 23 September 2026 AB “Novaturas” (hereinafter – the Company) received a report from its shareholder Mr. Neşet Koçkar (hereinafter – the Offeror) on the implementation of the mandatory non-competitive tender offer.

Through the implementation period of the tender offer the Offeror bought-up 3,153,045 ordinary registered shares of the Company, with nominal value of EUR 0.03 (three cents) each (ISIN code LT0000131872), which represent 17.42 percent of all the shares of the Company.

The report on the implementation of the tender offer is attached hereto.

Aleksejs Kriščuks
CEO
investors@novaturas.lt 

Attachment

The All-in-one system combines plates, cannulated screws and specialized instrumentation to streamline complex pelvic surgery

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the launch of the EVOS PELVIC Plating System, the next evolution of the EVOS plating platform designed to address the unique challenges of pelvic and acetabular surgery.

EVOS PELVIC System is built on the proven principles of the EVOS platform that has become a trusted choice for trauma surgeons worldwide due to its breadth of implant offerings, procedural efficiency and clinically relevant innovation.1-5  EVOS PELVIC System helps surgeons address a broad range of fracture patterns and disruptions in highly complex procedures. Dedicated plates and instruments are designed to work seamlessly together to support plate-assisted reduction.

The EVOS PELVIC System delivers a complete, all-in-one solution featuring:

  • Pre-contoured plate options for the posterior wall, quadrilateral surface, and pubic symphysis.
  • Locking and non-locking utility plates.
  • A new cannulated screw system designed specifically for the pelvis and acetabulum.
  • Specialized instrumentation to support exposure, fracture reduction and implant placement.

“The launch of EVOS PELVIC System marks an important milestone in the continued expansion of our EVOS Plate portfolio and our commitment to advancing trauma care,” said Nate Folkert, President, Smith+Nephew Orthopaedics. “We are excited to bring this next evolution of the EVOS Platform to surgeons and patients around the world.”

“The brand EVOS was created from our mission to drive the Evolution of Osteosynthesis,” said John Rawlinson, Senior Director, Global Marketing, Smith+Nephew. “Our goal is to deliver meaningful innovation that helps surgeons address complex clinical challenges and underscores the company’s continued investment in solutions that help improve outcomes. The new EVOS PELVIC System is a powerful example of that mission in action.”

“We set out to develop what we believe is the most comprehensive pelvic and acetabular fracture system to date,” said Dr. Reza Firoozabadi, MD, Professor of Orthopedic Surgery at the University of Washington/Harborview Medical Center and design surgeon for the EVOS PELVIC System. “It was designed to address the full spectrum of injuries, from straightforward to the most complex pelvic ring and acetabular fractures, while providing fixation options for patients ranging from young individuals to elderly patients with compromised bone quality.”

“Specific implants and instruments were designed to work together to facilitate plate-assisted reduction, giving surgeons the ability to obtain a reduction, fine-tune it using features engineered into the plates and instruments, and then maintain that reduction until fracture union has occurred,” Dr. Firoozabadi explained. “Ultimately, our goal was to make these technically demanding procedures more efficient and reproducible, allowing surgeons to focus on achieving the best possible reduction and fixation for their patients.”

The EVOS PELVIC System is currently available in the United States. Availability and timing of launch in other markets may vary. It will be available for surgeons to preview at Smith+Nephew’s booth #301 during the upcoming 2026 Orthopaedic Trauma Association (OTA) Annual Meeting in Nashville, TN September 23-26. Make plans to visit Smith+Nephew’s Mini Surgical Suite located in the Exhibit Hall at the Music City Convention Center for an exclusive opportunity to connect one-on-one with the EVOS PELVIC System design surgeons.

For more information about the EVOS PELVIC System, visit the EVOS PELVIC web page.

– ends –

Media Enquiries
Gina Kamler                       
+1 (901) 262-9070
gina.kamler@smith-nephew.com

References

1. Smith+Nephew 2020.EVOS Large Frag Lateral Proximal Tibia Plate Validation Lab. Internal Report.

2. Smith+Nephew 2020.EVOS Large Frag Proximal Humerus Plate Validation Lab. Internal Report.

3. Smith+Nephew 2019.EVOS Large Frag Medial Distal Femur Plate Validation Lab. Internal Report.

4. Smith+Nephew 2020.EVOS Large Frag Straight Plate Validation Lab. Internal Report.

5. Smith+Nephew 2020.EVOS Large Frag Peri-Prosthetic Proximal Femur Plate Validation Lab. Internal Report.

About Smith+Nephew

Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 17,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.

Founded in Hull, UK, in 1856, we now operate in around 100 countries, and generated annual sales of $6.2 billion in 2025. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on LinkedIn, Instagram or Facebook.

Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as “aim”, “plan”, “intend”, “anticipate”, “well-placed”, “believe”, “estimate”, “expect”, “target”, “consider” and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew’s most recent annual report on Form 20-F, which is available on the SEC’s website at www. sec.gov, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew’s expectations.

Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office.

CEO increases direct ownership to more than 23 million shares, including an additional open-market purchase, further aligning his interests with shareholders and reflecting confidence in Eva Live’s long-term strategy and growth potential.

LOS ANGELES, Sept. 23, 2026 (GLOBE NEWSWIRE) — Eva Live Inc. (Nasdaq: GOAI) (“Eva Live” or the “Company”) today announced that its Chief Executive Officer, David Boulette, has acquired an aggregate of 4,221,425 shares of the Company’s common stock, including transactions reported in a Form 4 filed with the U.S. Securities and Exchange Commission on September 21, 2026 and an additional open-market purchase.

The transactions included 4,000,000 shares at $0.10 per share, representing a value of $400,000; 202,947 shares at $2.28 per share, representing a value of approximately $462,719; and an additional 18,478 shares purchased in the open market at an average price of approximately $2.03 per share, representing an additional investment of approximately $37,510.

The combined value of the 4,221,425 shares acquired was approximately $900,229.

Following these transactions, Mr. Boulette’s direct ownership increased to approximately 23,043,478 shares of Eva Live common stock, significantly aligning his personal equity interests with those of the Company’s shareholders.

Mr. Boulette’s increased ownership reflects his confidence in Eva Live’s long-term strategy and his belief in the Company’s underlying businesses, technology portfolio, growth initiatives and opportunities for long-term value creation.

Eva Live continues to execute on its strategy of developing and commercializing technology-driven businesses, with a focus on artificial intelligence, digital marketing, lead generation and other scalable technology opportunities.

The Company has continued to expand its technology platform and commercial initiatives, including the development of Eva Brain, its autonomous AI marketing technology, and FastQuoteDirect.com, its digital lead-generation platform.

Management believes these initiatives, together with the Company’s broader technology and commercialization strategy, provide Eva Live with multiple opportunities to expand its business and pursue long-term revenue growth.

CEO Commentary

“I continue to believe strongly in the future of Eva Live and the business we are building,” said David Boulette, Chief Executive Officer of Eva Live.

“Increasing my ownership in the Company further aligns my interests with those of every GOAI shareholder. We have invested significant time and resources into developing our technology, expanding our platforms and positioning Eva Live to capitalize on opportunities across artificial intelligence, digital marketing and technology-driven lead generation.”

“While public markets can fluctuate significantly in the short term, my focus remains on the underlying business and our ability to execute our strategy. I believe the opportunities ahead of Eva Live are substantial, and my increased equity ownership reflects my confidence in the Company’s long-term direction and potential.”

“Our objective is straightforward: execute our business plan, grow our operating businesses and work toward creating sustainable long-term value for our shareholders.”

Management remains focused on disciplined execution, commercialization of its technology platforms, revenue growth and strengthening Eva Live’s position across its core and emerging business segments.

About Eva Live Inc.

Eva Live Inc. (Nasdaq: GOAI) is a technology company focused on developing and commercializing artificial intelligence, digital marketing, lead-generation and other technology-driven platforms designed to address large and growing markets.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable federal securities laws. These statements include, among other things, statements regarding Eva Live’s business strategy, commercialization efforts, growth opportunities, technology platforms, future revenue potential and ability to create long-term shareholder value. Forward-looking statements are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied. Investors are encouraged to review Eva Live’s filings with the U.S. Securities and Exchange Commission for a discussion of risks and uncertainties affecting the Company. Eva Live undertakes no obligation to publicly update any forward-looking statement except as required by applicable law.

Media Inquiries:

Javan Khazali
Phone: 310-229-5981
Email: info@eva.live

Website: @eva.live
Instagram: @eva.liveinc
Facebook: @evaliveinc
X: @evaliveinc1
LinkedIn: @eva-live
Youtube: @evaliveinc

Míla Holding hf.
Storhofdi 22-30,
110 Reykjavik,
Iceland

Míla Holding hf. announces Consolidated Condensed Interim Financial Statements for the six months ended June 30, 2026 (MILA 300929 bond )

Consolidated condensed interim financial statements, for the six months ended June 30, 2026 of Míla Holding hf. were approved at a Board of Directors meeting on 22 September 2026.

The financial statements can be found on the Company’s website: https://www.mila.is/um-milu/fjarmal/

For more information please contact:
Inga Helga Halldórudóttir
Compliance officer
Míla Holding hf.
ingah@mila.is

Attachments

New enterprise SEO and AI search platform marks commercial deployment of IndexR technology under strategic Revvim licensing agreement

AVENTURA, Fla., Sept. 23, 2026 (GLOBE NEWSWIRE) — Moon Equity Holdings Corp. (OTC: MONI) today announced the official commercial launch of RevvEO, Revvim’s new enterprise SEO and AI search optimization platform, powered by IndexR.ai.

The launch represents a significant commercialization milestone for IndexR following the strategic go-to-market licensing agreement announced by Moon Equity Holdings and Revvim in June 2026.

RevvEO transforms traditional SEO and emerging AI-search optimization into an actionable, revenue-focused operating system. Rather than simply presenting marketing teams with additional dashboards and data, RevvEO analyzes search performance, website structure, AI visibility and business economics to determine what work should be done first and what that work is potentially worth to the business.

“RevvEO represents exactly what we set out to accomplish with IndexR—turn an enormous amount of fragmented search and AI data into clear, measurable actions that businesses can actually execute,” said Steven Marshall, CEO of Moon Equity Holdings Corp. and founder of IndexR.ai. “Seeing this technology move from development, to testing, to licensing and now into a commercially available Revvim product is an important milestone for both IndexR and Moon Equity Holdings.”

From Search Data to Ranked Business Priorities

RevvEO connects with a customer’s existing search data, crawls the company’s website and evaluates its presence across both traditional search and emerging AI answer environments.

The platform then generates a prioritized list of actions ranked according to their potential business value.

Customers can provide metrics including average order or deal value and conversion rate, allowing RevvEO to incorporate company-specific economics into its prioritization model.

Each recommended task can include a priority score, estimated effort level, assigned owner, implementation checklist and acceptance criteria, providing marketing teams with an operational workflow rather than another layer of analytics.

After work is completed, RevvEO re-crawls the environment to verify implementation and measures subsequent changes in revenue performance.

Measuring Visibility Across the New AI Search Landscape

RevvEO also addresses one of the fastest-growing challenges facing brands: understanding whether and how they appear inside AI-generated answers and are prepared for the world of agentic customers..

The platform tracks brand visibility across major generative and answer-engine environments, including:

  • ChatGPT
  • Google AI Overviews
  • Google AI Mode
  • Gemini
  • Perplexity

That AI visibility becomes another input into RevvEO’s prioritization system, enabling companies to manage traditional SEO, Generative Engine Optimization, Answer Engine Optimization and AI visibility combined with agentic purchasing optimization (APO) as interconnected parts of a broader search strategy.

Unlike monitoring approaches centered on a limited list of manually selected prompts or keywords, RevvEO is designed to continuously evaluate the ever changing broader search and AI landscape.

“Search is no longer just about ranking ten blue links on Google,” Marshall continued. “Customers are now discovering companies, products and information through a rapidly expanding ecosystem of AI-generated answers. Companies have to accept that their customers now include AI Agents purchasing their items to complete their tasks. Businesses need to know not just where they are visible but how to get in front of these agentic customers and most importantly, which actions will have the greatest economic impact. RevvEO was designed around that fundamental change.”

Commercialization of the IndexR Technology Platform

The RevvEO launch follows the June 30, 2026 strategic go-to-market licensing agreement between Moon Equity Holdings, IndexR and Revvim covering IndexR’s next-generation enterprise AI Visibility and Revenue Operations technology (AIVROS).

Under that agreement, Revvim assumed responsibility for commercialization, enterprise sales, customer onboarding, support and lifecycle management while incorporating IndexR technology into Revvim-branded products carrying the “Powered by IndexR.ai” designation.

The agreement was designed to combine IndexR’s technology development with Revvim’s established enterprise marketing technology infrastructure, customer relationships and agency distribution network.

Revvim now has more than 400 enterprise customers and over 100 digital marketing agencies, providing an established channel through which the jointly commercialized technology can be introduced to enterprise marketers.

The official launch of RevvEO represents the transition of that agreement from go-to-market preparation into a publicly available commercial product.

RevvEO Early Access Program

Revvim is currently offering qualified customers and agency partners access to the full RevvEO platform through a 30-day early access program.

According to Revvim, setup can be completed in approximately five minutes, with the initial analysis and ranked task list generated during the first session. Access to customer systems is read-only and does not modify the customer’s website.

Additional information regarding RevvEO is available through Revvim.

About Moon Equity Holdings Corp.

Moon Equity Holdings Corp. (OTC: MONI) is a publicly traded technology company focused on next-generation data, search, artificial intelligence and infrastructure technologies designed to improve enterprise visibility, analytics and operational intelligence.

Through IndexR.ai and its strategic technology relationships, Moon Equity Holdings is developing and commercializing technologies designed for the rapidly evolving AI, search and enterprise data markets.

About IndexR.ai

IndexR.ai, a wholly owned subsidiary of Moon Equity Holdings Corp., develops advanced search, data and artificial intelligence technologies designed to organize, analyze and transform large-scale information into actionable intelligence.

IndexR’s technology portfolio includes AI-driven search visibility, optimization, analytics, workflow and data infrastructure technologies for enterprise applications.

About Revvim

Revvim is an enterprise AI and digital marketing technology company specializing in search performance, revenue optimization, paid-search efficiency, workflow automation and AI-driven marketing solutions for enterprise brands and agencies.

Revvim develops technology designed to help marketing organizations translate search performance and competitive intelligence into measurable business outcomes.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable federal securities laws. Forward-looking statements include statements regarding the commercialization, adoption, market opportunity, capabilities, anticipated customer demand and potential financial or operational impact of RevvEO, IndexR technologies and the strategic relationship between Moon Equity Holdings, IndexR and Revvim.

Forward-looking statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks include, among others, customer adoption, competitive market conditions, technological developments, commercialization timing, pricing, operating costs, third-party relationships and other risks applicable to emerging technology businesses.

Readers are cautioned not to place undue reliance on forward-looking statements. Moon Equity Holdings Corp. undertakes no obligation to publicly update or revise any forward-looking statements except as required by law.

Media & Investor Inquiries

Moon Equity Holdings Corp. / IndexR.ai
Email: press@indexr.ai

Tornator Oyj, Stock Exchange release 23 September 2026 at 18.00 EET

Listing prospectus for Tornator Oyj’s EUR 300 million green notes available; listing application submitted

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, TO ANY PERSON LOCATED OR RESIDENT IN, OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE AND SOUTH AFRICA, OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

Tornator Oyj (“Tornator“) announced on 16 September 2026 its decision to issue rated senior secured green notes in the aggregate principal amount of EUR 300 million (the “Notes“). The Notes were issued on 23 September 2026. The Notes will mature on 23 January 2033 and carry a fixed interest at the rate of 4.5 per cent. per annum. The Notes were issued in accordance with Tornator’s green finance framework (the “Framework“) published in April 2026. Tornator’s senior secured rating is Baa3, with a stable outlook, by Moody’s Ratings. Moody’s Ratings has assigned a Baa3 credit rating to the Notes.

The Finnish Financial Supervisory Authority has today approved the listing prospectus of the Notes. The listing prospectus will be available in English on Tornator’s website at Debt investors – Tornator

Tornator has today submitted an application for the Notes to be admitted to trading on the official list of sustainable bonds of Nasdaq Helsinki Ltd. Trading on the Notes is expected to commence on 25 September 2026 under the trading code “TORJ450033”.

Tornator shall use the net proceeds from the issue of the Notes to refinance and finance Tornator’s existing indebtedness, including redeeming the EUR 350m 1.250% notes due 14 October 2026 (ISIN: FI4000442108). An amount equivalent to the net proceeds of the Notes will be used for financing and refinancing eligible green assets in accordance with Tornator’s Framework.

Danske Bank A/S, OP Corporate Bank plc and Skandinaviska Enskilda Banken AB (publ) acted as Joint Lead Managers for the issue of the Notes.

Further information:
Antti Siirtola, CFO, tel. +358 40 773 0975

www.tornator.fi/en

Tornator is a leading European company specialising in sustainable forestry. It owns forests in Finland, Estonia and Romania. In 2025, the Group’s revenue totalled approximately EUR 232 million and its balance sheet amounted to about EUR 4.0 billion. The Group directly employs around 190 people. Altogether, the company’s forests provide approximately 1,600 full time equivalent jobs through Tornator’s own personnel as well as entrepreneurs and their employees. The parent company’s owners are Finnish, mainly institutional investors. Tornator’s mission is to create sustainable well being from forests.

Important information

This release is for information purposes only and is not to be construed as an offer to purchase or sell or a solicitation of an offer to purchase or sell with respect to any securities of Tornator. The distribution of this release and the related material concerning the issuance of the Notes may, in certain jurisdictions, be restricted by law. Persons into whose possession this release or any such offering material or documentation may come are required to inform themselves of and observe all such restrictions. This release and any such offering material or documentation may not be distributed or published in any country or jurisdiction if to do so would constitute a violation of the relevant laws of such jurisdiction or would require actions under the laws of a state or jurisdiction. In particular, this release and any such offering material or documentation may not be distributed in the United States, Australia, Canada, Hong Kong, Japan, New Zealand, Singapore or South Africa and this release and any related material concerning the issuance of the Notes may not be sent to any person in the before mentioned jurisdictions, except under circumstances that will result in compliance with any applicable laws and regulations.

The Notes will not be registered under the U.S. Securities Act 1933, as amended (the “Securities Act”) or with any securities regulatory authority of any state of the United States. The Notes may not be offered, sold, pledged or otherwise transferred directly or indirectly within the United States or to, or for the account or benefit of, U.S. Persons (as defined in Regulation S under the Securities Act (“Regulation S”)), except to a person who is not a U.S. Person (as defined in Regulation S) in an offshore transaction pursuant to Regulation S.

The Notes are not intended to be offered, sold, distributed or otherwise made available to and should not be offered, sold, distributed or otherwise made available to any retail investor in the United Kingdom (the “UK”). For the purposes of this provision, a retail investor means a person who is either one (or both) of the following: (i) not a professional client, as defined in point (8) of Article 2(1) of Regulation (EU) No 600/2014 as it forms part of domestic law by virtue of the EUWA; or (ii) not a qualified investor as defined in paragraph 15 of Schedule 1 to the Public Offers and Admissions to Trading Regulations 2024. Consequently, no disclosure document required by the FCA Product Disclosure Sourcebook (DISC) for offering, selling or distributing the Notes or otherwise making them available to retail investors in the UK has been prepared and therefore offering, selling or distributing the Notes or otherwise making them available to any retail investor in the UK may be unlawful under DISC and the Consumer Composite Investments (Designated Activities) Regulations 2024.

Attachment

Originally published on CVS Health Company Newsroom

WOONSOCKET, R.I., SEPTEMBER 23, 2026 /3BL/ — CVS Health® (NYSE: CVS) recently announced the launch of its nationwide “Wear Your HeART” Bandage Art Contest, inviting people across the United States to submit original artwork inspired by the importance of protecting personal, family and community health.

The contest offers artists, students, families and community groups an opportunity to turn their creativity into a source of inspiration for millions of Americans. Four Grand Prize winners will have their designs featured on limited-edition CVS brand adhesive bandages that will be used in CVS Pharmacy® locations nationwide for immunizations beginning in Fall 2027. Winners will be recognized on related promotional materials and receive $5,000.

“Protection can look different for everyone, whether it’s getting vaccinated, caring for a loved one, or taking small steps to stay healthy,” said Erin Condon, Chief Marketing Officer, Pharmacy and Consumer Wellness, CVS Health. “Through this contest, we’re inviting people to share their unique perspectives on what it means to protect their health and their communities.”

Contest Details

The “Wear Your HeART” Bandage Art Contest is open to legal residents of the United States. Adults age 18 and older may enter on their own behalf, while entries from those under age 18 must be submitted by a parent, legal guardian or another adult age 18 or older.

Participants may enter individually or as part of a group. Each person or group is limited to one entry.

Artwork submissions should creatively reflect a design inspired by what protecting their health means to them and designs must include the CVS heart as part of the artwork.

Entries will be evaluated based on several criteria, including:

  • Story and impact: Clear, compelling and authentic storytelling and a demonstrated understanding of the “Protect Your Health” theme
  • Creativity and expression: Original and unique artwork that adheres to contest theme
  • Execution and quality: Completion of all submission requirements and demonstrated effort and attention to detail
  • Brand alignment: Thoughtful incorporation of the CVS Health heart within the design

Judging Process

Following the submission period, entries will undergo an initial review by a panel of judges. Finalists may advance to additional evaluation phases before final selections are made.

A panel of CVS Health judges will select four Grand Prize winners in accordance with the official judging criteria. Selected winners will be notified directly and announced publicly in January 2027.

How to Enter

Eligible participants can submit their design and required information at CVSWearYourHeART.com between September 15, 2026 and November 30, 2026. Required submission information includes contact details, city and state of residence, and, for entrants under age 18, information and consent from a parent or legal guardian.

Official contest rules, eligibility requirements and complete submission instructions are available at CVSWearYourHeART.com.

NO PURCHASE NECESSARY. Void where prohibited. The CVS® Wear Your HeART Contest is sponsored by CVS Pharmacy, Inc. Open to legal residents of the 50 U.S. and DC. Individuals under the age of 18 must have their parent or legal guardian enter on their behalf. Begins at 9:00 a.m. ET on 9/15/26 & ends 11:59 p.m. ET on 11/30/26. For complete eligibility details and official rules, visit CVSWearYourHeART.com.

###

About CVS Health

CVS Health is a leading health solutions company simplifying health care one person, one family and one community at a time. As of June 30, 2026, the Company had approximately 9,000 retail pharmacy locations, more than 1,000 walk-in and primary care medical clinics and a leading pharmacy benefits manager with approximately 87 million plan members. The Company also serves an estimated 37 million people through a broad range of health insurance products and related services. The Company’s integrated model uses personalized, technology driven services to connect people to simply better health, increasing access to quality care, delivering better outcomes, and lowering overall costs.

Media contact 

Amy Thibault
401-318-2865
Amy.Thibault@CVSHealth.com

 

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.